380
Participants
Start Date
August 21, 2017
Primary Completion Date
December 19, 2018
Study Completion Date
December 19, 2018
glecaprevir (300mg)/pibrentasvir (120mg)
glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
Auckland City Hospital, Auckland
East Sydney Doctors, Sydney
St Vincent's Hospital Sydney, Sydney
The Alfred Hospital, Melbourne
Inselspital - Universitaetsspital Bern, Bern
St Vincent's Hospital Melbourne, Melbourne
University Hospital Zurich, Zurich
New York University Langone Medical Center, New York
zibp - Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, Berlin
Hopital Saint Joseph, Marseille
Duke University Medical Center, Durham
Hannover Medical School, Hanover
Center for HIV and Hepatogastroenterology, Düsseldorf
CIM-Centrum fuer Interdisziplinaere Medizin GmbH, Münster
SSM Health Dean Medical Group, Madison
Hopital Saint Antoine, Paris
Hopital Henri Mondor, Créteil
Beth Israel Deaconess Medical Center, Boston
Holdsworth House Medical Practice, Sydney
Royal Adelaide Hospital, Adelaide
Calder Center, Auckland
Christchurch Hospital, Christchurch
Dunedin Hospital, Dunedin
Lair Centre, Vancouver
(G.I.R.I.) GI Research Institute, Vancouver
William Osler Health System, Brampton
St Joseph's Healthcare Hamilton, Hamilton
Toronto General Hospital, Toronto
McGill University Health Centre (MUHC), Montreal
CHU de Québec-Université Laval, Québec
Barts Health, London
King's College Hospital, London
Imperial College Healthcare NHS Trust (St Mary's Hospital), London
Lead Sponsor
Kirby Institute
OTHER_GOV